

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-28** | Period of Report: **2013-01-28**
SEC Accession No. [0001354488-13-000327](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

PERNIX THERAPEUTICS HOLDINGS, INC.

CIK: [1024126](#) | IRS No.: [330724736](#) | State of Incorporation: **MD** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: [001-14494](#) | Film No.: [13551071](#)
SIC: **2834** Pharmaceutical preparations

Mailing Address
*33219 FOREST WEST
STREET
MAGNOLIA TX 77354*

Business Address
*33219 FOREST WEST
STREET
MAGNOLIA TX 77354
(832) 934-1825*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2013

PERNIX THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Maryland
*(State or other jurisdiction
of incorporation)*

001-14494
(Commission File Number)

33-0724736
(IRS Employer Identification No.)

10003 Woodloch Forest Drive
The Woodlands, TX
(Address of principal executive offices)

77380
(Zip Code)

Registrant's telephone number, including area code: (832) 934-1825

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events

On January 28, 2013, Pernix Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing it is scheduled to ring The NASDAQ Stock Market Opening Bell on January 28, 2013 to celebrate the Company’s listing on The NASDAQ Global Market. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated in this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press release by Pernix Therapeutics Holdings, Inc. dated January 28, 2013

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PERNIX THERAPEUTICS HOLDINGS, INC.

Dated: January 28, 2013

By: /s/ Cooper C. Collins

Cooper C. Collins

Chief Executive Officer & President

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release by Pernix Therapeutics Holdings, Inc. dated January 28, 2013



Company Contact:
 Joseph T. Schepers
 Director, Investor Relations
 (800) 793-2145 ext. 3002
jschepers@pernixtx.com

Pernix Therapeutics To Ring The NASDAQ Stock Market Opening Bell

THE WOODLANDS, TEXAS, January 28, 2013 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it is scheduled to ring The NASDAQ Stock Market Opening Bell at 9:30 am EST on Monday, January 28, 2013 to celebrate the Company's listing on the NASDAQ Global Market. The Company's common stock will begin trading on the NASDAQ on January 28, 2013.

Access to the NASDAQ MarketSite webcam feed is available to view the ceremony live by launching this link, <http://www.nasdaq.com/about/marketsitetowervideo.aspx> at 9:20 a.m. EST. To watch, under the heading MarketSite at the bottom of the page click on Windows Media Player.

Cooper Collins, President and CEO of Pernix, said, “We are pleased to ring the NASDAQ Opening Bell, celebrating our new listing and recent completion of the acquisition of Cypress Pharmaceuticals and Hawthorn Pharmaceuticals.”

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals' product line. The Company's branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company's branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The Company's wholly-owned subsidiary, Great Southern Laboratories, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. A product candidate utilizing cough-related intellectual property is in development for the U.S. OTC market. Founded in 1996, the Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company's website located at www.pernixtx.com.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements. Because these statements reflect the Company's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. No assurances can be given regarding the Company's future performance. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors.

These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.